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Aims: Presently, data on the association between nonalcoholic fatty liver disease (NAFLD) and distal
symmetric polyneuropathy in people with diabetes are scarce and conﬂicting. The aim of this retrospective,
cross-sectional study was to examine whether NAFLD was associated with an increased prevalence of distal
symmetric polyneuropathy in type 1 diabetic adults.
Methods: We studied all white type 1 diabetic outpatients (n = 286, 42.3% male, mean age 43 ± 14 years,
median diabetes duration 17 [10–30] years), who participated in a foot screening program at our adult
diabetes clinic after excluding those who had excessive alcohol consumption and other known causes of
chronic liver disease. NAFLD was diagnosed by ultrasonography. Distal symmetric polyneuropathy was
detected using the Michigan Neuropathy Screening Instrument method and the biothesiometer Vibrotest.
Results: Overall, the prevalence rates of NAFLD and distal symmetric polyneuropathy were 52.4% and 35.3%,
respectively. Patients with NAFLD had a substantially increased prevalence of distal symmetric poly-
neuropathy compared to their counterparts without NAFLD (51.0% vs. 17.1%, p b 0.001). In univariate analysis,
NAFLD was associated with an approximately 5-fold increased risk of prevalent distal symmetric
polyneuropathy (odds ratio [OR] 5.32, 95% conﬁdence interval [CI] 3.1–9.3, p b 0.001). This association
remained signiﬁcant even after adjustment for age, sex, diabetes duration, hemoglobin A1c, diabetic
retinopathy, smoking, metabolic syndrome, chronic kidney disease and carotid artery stenoses ≥ 40%
(adjusted-OR 2.23, 95% CI 1.1–4.8, p b 0.05).
Conclusions: Our results show that NAFLD, diagnosed by ultrasonography, is strongly associated with an
increased risk of distal symmetric polyneuropathy in type 1 diabetic adults, independently of several
cardio-metabolic risk factors.© 2017 Elsevier Inc. All rights reserved.1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease worldwide (occurring in up to 30% of adults in
Western countries) and has now become the second most frequent
indication for liver transplantation in the United States with the
worrying prospect of becoming the ﬁrst indication in the coming
years.1–3
The prevalence of NAFLD in people with diabetes is much higher,
ranging from 50% to 75% in patientswith type 2 diabetes and from 40%
to 50% in those with type 1 diabetes.3,4 In addition, patients withconﬂicts of interest to disclose.
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(A. Mantovani).diabetes are more likely to develop the more severe histologic forms
of NAFLD, including nonalcoholic steatohepatitis (NASH), advanced
ﬁbrosis and cirrhosis.3,4 To date, convincing evidence indicates that
NAFLD is associated not only with considerable liver-related morbid-
ity and mortality, but also with an increased risk of cardiovascular
disease (CVD), chronic kidney disease (CKD) and other important
extra-hepatic complications both in patients without diabetes and in
those with type 1 or type 2 diabetes.5–9
In parallel, distal symmetric polyneuropathy, a chronic,
nerve-length-dependent, sensory and motor polyneuropathy, is the
most common form of diabetic neuropathy that affects at least one
third of patients with type 1 or type 2 diabetes.10–12 Notably, the
presence of distal symmetric polyneuropathy not only confers a
predisposition to painless foot ulcers and subsequent amputations,
but is also associated with an increased risk of all-cause and
CVD mortality.13–15 It is well known that poor glycemic control is
the strongest risk factor for the development of diabetic peripheral
1022 A. Mantovani et al. / Journal of Diabetes and Its Complications 31 (2017) 1021–1026neuropathy, but other important pathological conditions, such as
dyslipidemia, hypertension, diabetic retinopathy, nephropathy and
smoking, may play important roles.10,16–18 Given that all these risk
factors and pathological conditions are also strongly associated with
NAFLD (irrespective of pre-existing diabetes), and that NAFLD is
associated with an increased risk of diabetic nephropathy (another
chronic microvascular complication of diabetes),7,8 it is reasonable to
assume that there is an association between NAFLD and diabetic distal
symmetric polyneuropathy. Currently, however, published studies
that have evaluated the existence of such association are very few and
have produced conﬂicting results.19–21
Thus, the aim of this retrospective, observational study was to
assess whether NAFLD, as diagnosed by ultrasonography, was
associated with an increased prevalence of distal symmetric poly-
neuropathy in type 1 diabetic adults.
2. Methods
2.1. Patients
For the purpose of this study, we have retrospectively analyzed the
electronic records of all white outpatients with established type 1
diabetes (n = 563), who regularly attended our adult diabetes clinic
and accepted to participate in a foot-screening program (over the
years 2004–2012). The only exclusion criteria for participating in this
screening programwere the presence of foot ulcers, gangrene or prior
amputations. Type 1 diabetes was diagnosed by the typical presen-
tation of disease, the absolute dependence on insulin treatment for
survival, the presence of undetectable fasting C-peptide levels and the
presence of anti-islet cell auto-antibodies.10
We have subsequently excluded all patients with: (1) missing liver
ultrasound data (n = 184, 32.7%); (2) a history of end-stage renal
disease or malignancy (n = 6, 1%); and (3) a documented history of
cirrhosis of any etiology or chronic liver disease due to secondary
causes, such as excessive alcohol consumption (i.e., deﬁned as alcohol
consumption N30 g/day for men and N20 g/day for women,
respectively), viral hepatitis or use of steatogenic medications (n =
87, 15.4%).
As a consequence of this selection, 286 (50.8%) adult outpatients
with established type 1 diabetes (mean age 43 ± 14 years; 42.3%
male; median duration of diabetes 17 [10–30] years) were included in
the ﬁnal analysis. Details of the study design are summarized in
Supplemental Fig. 1.
No signiﬁcant differences were found in main demographic/
laboratory variables and frequency of distal symmetric polyneuro-
pathy between patients with (n = 286) and without (n = 184) liver
ultrasound examination (data not shown). It is important to note that
in our diabetes clinic an ultrasound examination of the liver is almost
routinely performed among the outpatients with diabetes.
The local ethics committee approved the study protocol. The
informed consent requirement for this study was exempted by the
ethics committee, because researchers only accessed retrospectively a
de-identiﬁed database for analysis purposes.
2.2. Clinical and laboratory data
Body mass index (BMI) was calculated by dividing weight in
kilograms by height in meters squared. Blood pressure was
measured in duplicate with a standard mercury manometer after
a rest of at least 5 min. Patients were considered as having
hypertension if their blood pressure was ≥130/85 mm Hg or if
they were taking any anti-hypertensive drugs. Detailed information
on smoking status, daily alcohol consumption and current use of
medications was obtained from all patients via interviews during
medical examinations.Venous blood was drawn in the morning after an overnight fast.
Serum lipids, creatinine (measured using a Jaffe ́rate-blanked and
compensated assay), liver enzymes and other biochemical blood
measurements were determined by standard laboratory procedures
on Siemens Dimension Vista (Siemens, Siemens Healthcare Diagnos-
tics Inc., Deerﬁeld, IL, USA). Normal ranges for serum alanine and
aspartate aminotransferase levels (ALT and AST) in our laboratory
were 10–40 U/l for both men and women. Normal ranges for serum
gamma-glutamyltransferase (GGT) levels were 5–50 units/l for
women and 5–55 U/l for men, respectively. LDL-cholesterol was
calculated by the Friedewald's equation. No patients had serum
triglyceride levels above 4.5 mmol/l. Hemoglobin A1c (HbA1c) was
measured by a high-performance liquid chromatography analyzer on
Tosoh G7 automated analyzer (Tosoh Bioscience Inc., San Francisco,
CA; USA); the upper limit of normal for our laboratory was 5.6% (38
mmol/mol). The estimated glomerular ﬁltration rate (eGFRMDRD) was
calculated by the 4-variable Modiﬁcation of Diet in Renal Disease
(MDRD) study equation.23 Albuminuria was measured using an
immuno-nephelometric method on a morning spot urine sample and
expressed as the albumin-to-creatinine ratio (ACR) on Beckman-
Coulter IMMAGE (Beckman-Coulter Instruments, Fullerton, CA; USA).
The presence of CKDwas deﬁned as an eGFRMDRD b 60ml/min/1.73m2,
macro-albuminuria (deﬁned as an urinary ACR N30 mg/mmol), or
both.
Metabolic syndrome was diagnosed by a modiﬁed Adult Treat-
ment Panel (ATP)-III deﬁnition, as waist circumference was available
only in few patients (n = 89). Accordingly with this modiﬁed ATP-III
deﬁnition,24,25 a patient with type 1 diabetes was classiﬁed as having
the metabolic syndrome if he/she had at least two of the following
four components: (i) BMI N28 kg/m2 in men or N27 kg/m2 in women;
(ii) triglycerides ≥1.7 mmol/l; (iii) HDL-cholesterol b1.0 mmol/l in
men and b1.29 mmol/l in women or receiving lipid-lowering drugs;
and (iv) blood pressure ≥ 130/85 mm Hg or receiving anti-
hypertensive drugs.
A single ophthalmologist diagnosed diabetic retinopathy using
fundoscopy after pupillary dilation according to a clinical disease
severity scale (no retinopathy, non-proliferative, proliferative or
laser-treated retinopathy). The presence of proliferative retinopathy
was conﬁrmed by fundus ﬂuorescein angiography. The presence of
atherosclerotic plaques (i.e., stenosis ≥40%) at the level of either the
internal or common carotid arteries was also detected by
echo-Doppler scanning in all patients.
2.3. Assessment of diabetic peripheral neuropathy
To assess diabetic peripheral neuropathy, we applied a validated
Michigan Neuropathy Screening Instrument method (MNSI), as
described elsewhere.22,26 Since this method was designed only for
screening purposes, the obtained results can be referred to ‘possible’
distal symmetric polyneuropathy. A trained nurse administered the
MNSI questionnaire to all our patients. This questionnaire consists of
15 “yes or no” questions, including one relevant to general asthenia
and one relevant to peripheral vascular disease, as described by the
Michigan Clinic.27 After administration of the MNSI questionnaire, we
also performed in all patients: (i) a foot inspection looking for the
presence of deformities (e.g., hammer toes, overlapping toes, hallux
valgus, joint subluxation, prominent metatarsal heads), dry skin,
callus, infection or ulceration; (ii) a non-invasive, quantitative
assessment of vibration sensation threshold (VPT) at the dorsum of
the great toe using a biothesiometer Vibrotest instead that a 128-Hz
tuning fork; and (iii) a grading of ankle reﬂexes (normal, reduced, or
absent). The results of physical examination were as follows: 1 point
in presence of alterations of the foot at inspection, 1 point to a
pathologic ankle reﬂex (0.5 point when evocable with the Jendrassik
maneuver), and 1 point to a VPT higher than 25 Volt. Evaluating both
feet, a maximum score of 8 points for each patient was possible.
Table 1
Clinical and biochemical characteristics of adult patients with type 1 diabetes stratiﬁed
by NAFLD status.
Variables Without NAFLD
(n = 136)
With NAFLD
(n = 150)
p Value
Sex (men, %) 36.0 48.0 0.027
Age (years) 38.8 ± 13.1 47.5 ± 14.2 b0.01
Diabetes duration (years) 13 (8–20) 24 (12–33) b0.01
BMI (kg/m2) 22.7 ± 3.4 26.1 ± 4.7 b0.01
Current smokers (%) 22.0 24.0 0.402
Systolic blood pressure (mm Hg) 124.5 ± 16.4 132.1 ± 17.4 b0.01
Diastolic blood pressure (mm Hg) 76.1 ± 7.9 79.7 ± 9.4 b0.05
Fasting glucose (mmol/l) 10.3 ± 4.2 10.8 ± 4.0 0.332
HbA1c (%) 7.8 ± 1.0 8.2 ± 1.2 0.011
Total cholesterol (mmol/l) 4.5 ± 0.9 4.9 ± 1.1 b0.01
LDL cholesterol (mmol/l) 2.5 ± 0.6 2.8 ± 0.9 b0.05
HDL cholesterol (mmol/l) 1.5 ± 0.4 1.3 ± 0.4 0.010
Triglycerides (mmol/l) 0.92 (0.7–1.2) 1.21 (0.8–1.9) b0.01
eGFRMDRD (ml/min/1.73 m2) 94 ± 25 83 ± 23 b0.01
Urinary ACR (mg/mmol) 1 (0.7–2.3) 4 (1.1–10) b0.01
AST (U/l) 17 (13–25) 18 (13–24) 0.091
ALT (U/l) 18 (14–24) 21 (14–29) b0.05
GGT (U/l) 14 (10–21) 21 (13–39) b0.01
Hypertension (%) 30.8 60.7 b0.01
Metabolic syndrome (%) 21.3 52.7 b0.01
CKD (%) 4.6 22.7 b0.01
Diabetic retinopathy, any degree (%) 54.8 73.9 b0.01
Carotid artery stenosis ≥40% (%) 1.0 9.3 b0.01
Daily total insulin units (U) 36 (25–48) 45 (32–61) b0.01
Anti-hypertensive therapy (%) 18.3 51.3 b0.01
Lipid-lowering therapy (%) 17.2 53.4 b0.01
Distal symmetric polyneuropathy (%) 17.1 51.0 b0.001
Sample size, n = 286. Data are expressed as means ± SD, medians and interquartile
ranges (IQR) or percentages. Abbreviations: ACR, urinary albumin-to-creatinine ratio;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, bodymass index;
CKD, chronic kidney disease; eGFRMDRD, estimated glomerular ﬁltration rate (by the
MDRD study equation); GGT, gamma-glutamyltransferase, HbA1c, hemoglobin A1c.
Notes: CKD was deﬁned as eGFRMDRD b 60 ml/min/1.73 m2 and/or macro-albuminuria;
metabolic syndrome was deﬁned by a modiﬁed ATP III deﬁnition; hypertension was
deﬁned as blood pressure ≥ 130/85 mm Hg or drug treatment.
Table 2
Logistic regression analyses—association between NAFLD and the risk of prevalen
distal symmetric polyneuropathy in adult patients with type 1 diabetes.
Logistic regression models Odds ratio 95% CI p Value
NAFLD (yes vs. no)
Unadjusted model 5.32 3.1–9.3 b0.001
Adjusted model 1 4.09 2.3–7.4 b0.001
Adjusted model 2 2.52 1.3–4.9 b0.01
Adjusted model 3 2.23 1.1–4.8 b0.05
Adjusted model 4 2.47 1.1–5.5 b0.05
Other independent predictors in adjusted model 3
Diabetes duration (years) 1.09 1.05–1.2 b0.001
HbA1c (%) 1.52 1.1–2.1 b0.01
Diabetic retinopathy (yes vs. no) 1.79 1.1–2.9 b0.05
Sample size, n=286. Data are presented as odds ratios (±95% conﬁdence intervals, CI)
by logistic regression analyses. Distal symmetric polyneuropathy was the dependen
variable in all regression models.
Other covariates included in these multivariate logistic regression models, along with
NAFLD, were as follows:model 1: adjusted for age and sex;model 2: adjustment for age
sex, duration of diabetes, HbA1c, smoking history and presence of the metabolic
syndrome (by amodiﬁed ATP III deﬁnition);model 3: adjustment for the same variables
included in model 2 plus CKD (i.e., eGFRMDRD b 60 ml/min/1.73 m2 and/or
macro-albuminuria), diabetic retinopathy and presence of carotid artery stenoses ≥
40%; model 4: adjustment for age, sex, duration of diabetes, HbA1c, smoking, BMI
hypertension (i.e., blood pressure ≥ 130/85 mm Hg or drug treatment), atherogenic
dyslipidemia, CKD, diabetic retinopathy and presence of carotid artery stenoses ≥ 40%
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further evaluation of sensitivity was performed by Semmes–
Weinstein monoﬁlament (a plastic handle connected to a nylon
monoﬁlament, which measures clinically signiﬁcant large-ﬁber
neuropathy by buckling at 10 g of force). Based on a 9-point score,
the monoﬁlament test was considered pathological when the patient
was not able to correctly detect more than 5 points.28 In the literature,
the number of points to be pressed (from one to ten) varies widely. In
this study, data on cardiovascular autonomic neuropathy were not
available.
2.4. Liver ultrasonography
Liver ultrasonography was performed by experienced radiologists,
who were blinded to the patients' clinical details. Hepatic steatosis
was diagnosed on the basis of characteristic ultrasonographic
characteristics, such as diffuse hyperechogenicity of the liver relative
to the kidneys, ultrasonography beam attenuation, and poor visual-
ization of the intrahepatic vessel borders and diaphragm.29 It is
known that ultrasonography has a good sensitivity and speciﬁcity for
detecting moderate-to-severe hepatic steatosis, while its sensitivity is
reduced when the hepatic fat inﬁltration detected by liver biopsy is
less than 25%–30%.30 In this study, a semi-quantitative ultrasono-
graphic scoring of the degree of hepatic steatosis was not available.
2.5. Statistical analysis
Data are expressed as means ± SD, medians and interquartile
ranges (IQR) or proportions. Differences in clinical and biochemical
characteristics of participants were assessed using the unpairedt
t
,
,
.Student's t test for normally distributed variables and the Mann–
Whitney U test for non-normally distributed variables (i.e., diabetes
duration, serum liver enzymes, triglycerides, albuminuria and daily
insulin dose). The chi-squared test was used to test for
between-group differences among the categorical variables (Table
1). Logistic regression analysis was used to examine the association
between NAFLD and risk of prevalent distal symmetric polyneuro-
pathy after adjustment for diabetes-related variables and other
potential confounding factors. As reported in Table 2, ﬁve forced-
entry logistic regression models were performed as follows: the ﬁrst
model was unadjusted; the second model was adjusted for age and
sex (adjustedmodel 1); and the thirdmodel was adjusted for age, sex,
diabetes duration, HbA1c, smoking history and presence of the
metabolic syndrome (adjusted model 2). The fourth model was
additionally adjusted for CKD, diabetic retinopathy and presence of
carotid artery stenoses ≥40% (adjusted model 3). Finally, we also
performed a ﬁfth model (adjusted model 4) adjusted for age, sex,
duration of diabetes, HbA1c, smoking, BMI, hypertension, atherogenic
dyslipidemia, CKD, diabetic retinopathy and presence of carotid artery
stenoses ≥ 40%. Covariates included in these multivariate logistic
regression models were chosen as potential confounding factors
based on their signiﬁcance in univariate analyses or based on their
biological plausibility. A p-value b0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using SPSS software,
version 21.0 (IBM Corp, Armonk, NY).
3. Results
Overall, 150 (52.4%) patients had NAFLD (i.e., hepatic steatosis on
ultrasonography among patients with no history of excessive alcohol
consumption or other known causes of chronic liver diseases), while
the remaining 136 (47.6%) patients did not. Moreover, the prevalence
of distal symmetric polyneuropathy in the entire sample was 35.3%
(n = 101). In our electronic database, the actual scores for MNSI
questionnaire, VPT and MNSI examination were available only for a
subgroup of 123 patients (43% of total) because only some operators
had also reported the actual scores, whereas others had reported
exclusively the semi-quantitative information about the severity of
distal symmetric polyneuropathy (i.e., mild, moderate, or severe)
without simultaneously reporting the actual scores for each MNSI
questionnaire, VPT or MNSI examination. Among patients with distal
1024 A. Mantovani et al. / Journal of Diabetes and Its Complications 31 (2017) 1021–1026symmetric polyneuropathy, the mean scores for MNSI questionnaire,
VPT and MNSI examination were 5.7 ± 2.9, 33.2 ± 7.4 Volt and 4.1 ±
1.3, respectively. Monoﬁlament testing was pathological in 41% of
these patients. Overall, approximately 50% of our patients with distal
symmetric polyneuropathy had a moderate-to-severe neuropathy.
By study design, no patients had foot ulcers and prior history of
amputations.
Table 1 summarizes the main clinical and biochemical character-
istics of adult patients with type 1 diabetes grouped by presence or
absence of NAFLD. Compared to those without NAFLD, patients with
NAFLD were older, more likely to be male and obese, had longer
duration of diabetes and higher values of systolic/diastolic blood
pressure, HbA1c, serum lipids, albuminuria and liver enzymes
(although many patients with NAFLD had fairly normal serum liver
enzyme levels). Moreover, they were also more likely to be treated
with lipid-lowering and anti-hypertensive drugs, and had lower
eGFRMDRD and greater prevalence of the ATP-III deﬁned metabolic
syndrome, CKD, diabetic retinopathy and carotid artery stenoses
≥40%. Notably, patients with NAFLD had a remarkably higher
prevalence of distal symmetric polyneuropathy compared with their
counterparts without NAFLD (51.0% vs. 17.1%, p b 0.001).
Fig. 1 shows the prevalence of distal symmetric polyneuropathy in
patients stratiﬁed by both NAFLD status and HbA1c tertiles (i.e., 1st
tertile: ≤7.5%, 2nd tertile: 7.6%–8.1%, and 3rd tertile: N8.1%). Patients
with NAFLD and in the 3rd tertile of HbA1c had the highest prevalence
of distal symmetric polyneuropathy, whereas those with NAFLD in the
1st tertile of HbA1c had the lowest prevalence of distal symmetric
polyneuropathy. Notably and most importantly, in each HbA1c tertile,
patients with NAFLD had always a signiﬁcantly higher prevalence of
distal symmetric polyneuropathy than those without NAFLD.
We also compared the baseline clinical and biochemical charac-
teristics of patients stratiﬁed by presence or absence of distal
symmetric polyneuropathy. Patients with distal symmetric poly-
neuropathy were older (50.7 ± 14 vs. 38.6 ± 12 years, p b 0.01), more
likely to be obese (BMI 25.6 ± 4.8 vs. 23.8 ± 4.2 kg/m2, p b 0.01) and
had a longer duration of diabetes (median and IQR: 30 [20–37] vs. 12
[8–20] years, p b 0.01) compared to those without distal symmetric
polyneuropathy. Moreover, they were also more likely to be treated
with lipid-lowering and anti-hypertensive drugs, and had signiﬁcant-
ly lower eGFRMDRD, higher values of albuminuria, serum ALT and GGT,
and greater prevalence of metabolic syndrome, CKD, diabetic
retinopathy or carotid artery stenoses ≥40% than those without0
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Fig. 1. Prevalence of distal symmetric polyneuropathy in adult patients with type 1
diabetes stratiﬁed simultaneously by both NAFLD status and tertiles of hemoglobin A1c
(i.e., 1st tertile: ≤7.5%, 2nd tertile: 7.6%–8.1%, and 3rd tertile: N8.1%). p-Values =
0.001–0.01 for between-group differences and p b 0.05 for the overall trend by the χ2
test.symmetric polyneuropathy (data not shown). Notably, NAFLD
prevalence was remarkably greater in patients with distal symmetric
polyneuropathy than in those without (76.5% vs. 38.0%, p b 0.01).
Table 2 shows the effect of adjustment for traditional CVD risk
factors and diabetes-related variables on the association between
NAFLD and the risk of distal symmetric polyneuropathy. In univariable
regression analysis, NAFLD was associated with an approximately
5-fold increased risk of prevalent distal symmetric polyneuropathy
(OR 5.32, 95% CI 3.1–9.3, p b 0.001). This association remained
signiﬁcant after adjustment for age and sex (model 1). Furthermore,
the strength of this association was only partially attenuated after
adjustment for age, sex, diabetes duration, HbA1c, smoking and
presence of themetabolic syndrome (model 2). Whenwe additionally
adjusted our results for the presence of CKD, diabetic retinopathy and
carotid artery stenoses ≥40% the strong association between NAFLD
and distal symmetric polyneuropathy remained unchanged (model
3). As also shown in Table 2, in regression model 3, other variables
(along with NAFLD) that were independently associated with distal
symmetric polyneuropathy were longer duration of diabetes, higher
HbA1c and presence of diabetic retinopathy. To examine whether the
inclusion of hypertension or anti-hypertensive treatment or blood
pressure values in the cluster of the metabolic syndrome might have
smoothed the impact of hypertension per se on distal symmetric
polyneuropathy, we have also performed a regression model 4 where
we adjusted for the individual components of themetabolic syndrome
(instead of the metabolic syndrome as a clinical category) and the
same set of covariates of model 3. Also in this case, the strong
association between NAFLD and distal symmetric polyneuropathy
remained essentially unchanged. Hypertension was not independent-
ly associated with distal symmetric polyneuropathy.
4. Discussion
Distal symmetric polyneuropathy, or diabetic peripheral neuro-
pathy, is very common and often the most difﬁcult microvascular
complication to diagnose and manage because it is frequently
asymptomatic and mostly untreatable, except for symptomatic
measures. Distal symmetric polyneuropathy is not only linked with
the development of foot complications and subsequent lower limb
amputations, but also strongly associated with an increased risk of
CVD complications in patients with type 1 or type 2 diabetes.13–15 For
instance, the EURODIAB IDDM Complications Study, including 2787
adult patients with type 1 diabetes, has clearly documented that distal
symmetric polyneuropathy is a powerful risk factor for future
mortality, exceeding even the effect of traditional CVD risk factors.14
Over the last decade, it has become increasingly evident that
NAFLD is associated not only with increased liver-related mortality
andmorbidity, but also with an increased prevalence and incidence of
CVD and CKD both in patients with and without diabetes.1–9
To our knowledge, this is the largest cross-sectional study aimed at
examining the association between ultrasound-diagnosed NAFLD and
distal symmetric polyneuropathy in type 1 diabetic adults of European
extraction.
The main ﬁndings of our study are as follows: (1) type 1 diabetic
adults with NAFLD on ultrasonography had a substantially higher
prevalence of distal symmetric polyneuropathy than those without
NAFLD; (2) when we stratiﬁed patients by NAFLD status and HbA1c
tertiles, patients with NAFLD in the highest tertile of HbA1c (i.e.,
N8.1%) had the greatest prevalence of distal symmetric polyneuro-
pathy, whereas patients with NAFLD in the 1st tertile of HbA1c had
the lowest prevalence of distal symmetric polyneuropathy; however,
it is important to remember that HbA1c level reﬂects only the
glycemic control of a relatively short period (approximately 3
months) and it is not a mean value of longer observation periods;
(3) logistic regression analysis showed that NAFLD was associated
with an approximately 5-fold increased risk of prevalent distal
1025A. Mantovani et al. / Journal of Diabetes and Its Complications 31 (2017) 1021–1026symmetric polyneuropathy; and (4) this association remained
statistically signiﬁcant even after adjustment for diabetes-related
variables (i.e., diabetes duration, HbA1c and diabetic retinopathy) and
established cardio-metabolic risk factors (including also the presence
of metabolic syndrome features).
Previous epidemiological studies have reported a high prevalence
of the metabolic syndrome (ranging from 20% to 50%) in type 1
diabetic adults31,32 that might confer a predisposition to develop
NAFLD in this patient population. Notably, our ﬁndings conﬁrm
previous observations demonstrating that NAFLD is a highly prevalent
pathologic condition in type 1 diabetic adults that affects up to 50% of
these patients.33–35 Moreover, our ﬁndings also extend previously
published studies that have shown that ultrasound-diagnosed NAFLD
is associated with an increased prevalence of asymptomatic/symp-
tomatic CVD33 as well as an increased risk of CKD and diabetic
retinopathy in patients with type 1 diabetes, independently of several
cardio-renal risk factors.34–36 Collectively, these ﬁndings call for a
more active and systematic search for NAFLD in type 1 diabetic adults.
At present, published studies that examined the existence of an
association between NAFLD and distal symmetric polyneuropathy are
very few, have provided conﬂicting results and have been conducted
mainly in Asian populations with type 2 diabetes.19–21 In fact, in a
retrospective study involving 927 South Korean patients with type 2
diabetes, Kim et al.19 did not ﬁnd any signiﬁcant difference in the
prevalence of diabetic peripheral neuropathy among patients with
and without NAFLD. Lv et al.20 showed that NAFLD on ultrasonogra-
phy was associated with lower prevalence rates of both distal
symmetric polyneuropathy and diabetic nephropathy in a sample of
1217 Chinese inpatients with type 2 diabetes. More recently,Williams
et al.21 studied two small cohorts of Australian diabetic people from a
tertiary diabetes center (cohort 1, n = 456 with type 1 or 2 diabetes,
and cohort 2, n= 106 with type 2 diabetes). All underwent a detailed
assessment, including VPT measurement. NAFLD ﬁbrosis score, a
non-invasive marker of advanced ﬁbrosis, was calculated for all with
available data. Cohort 2 also had liver ultrasound examination and
transient elastography. These investigators reported that higher VPT
was signiﬁcantly associated with higher markers of liver ﬁbrosis due
to NAFLD in both cohorts. Moreover, in this study, higher NAFLD
ﬁbrosis score was also associated with a greater risk of progression of
VPT over a median period of 2.2 years.21
The most obvious explanation for our ﬁndings is that the strong
association between NAFLD and distal symmetric polyneuropathy
arises from the coexistence of established risk factors for diabetic
neuropathy, such as longer duration of diabetes, poor glycemic
control, smoking history, presence of metabolic syndrome, diabetic
retinopathy or CKD. However, it is important to underline that, in our
study, the association between NAFLD and the risk of prevalent distal
symmetric polyneuropathy remained statistically signiﬁcant even
after adjusting for all these coexisting clinical risk factors. This ﬁnding
strongly suggests that additional NAFLD-related mechanisms, beyond
of the shared cardio-metabolic risk factors, might be, at least in part,
responsible for the association between NAFLD and distal symmetric
polyneuropathy. To date, a clear understanding of the pathophysio-
logical pathways linking NAFLD to the development of distal
symmetric polyneuropathy remains elusive. However, accumulating
evidence suggests that NAFLD, especially in its necro-inﬂammatory
form (NASH), exacerbates hepatic and peripheral insulin resistance,
confers a predisposition to atherogenic dyslipidemia, and causes the
release of several proinﬂammatory, procoagulant, prooxidant and
proﬁbrogenic mediators3,5–7,37,38 that may play important roles in the
pathophysiology of distal symmetric polyneuropathy. For example,
some studies suggested that atherogenic dyslipidemia may directly
induce nerve damage through lipotoxicity of free fatty acids and,
indirectly, by free fatty acids stimulating a systemic inﬂammatory
cytokine cascade and increasing insulin resistance.38,39 Furthermore,
several experimental studies have clearly demonstrated that proin-ﬂammatory and prooxidant mediators play a central role in the
pathophysiology of distal symmetric polyneuropathy.11,39–42 Howev-
er, further studies are required to better elucidate the underlying
mechanisms by which NAFLDmay contribute to the development and
progression of distal symmetric polyneuropathy.
Our study has some important limitations that should be
mentioned. Firstly, the retrospective, cross-sectional design of the
study limits our ability to determinate the causality and temporality of
these observations. Secondly, we cannot exclude a possible selection
bias of excluding patients who had missing liver ultrasound
examinations (although no signiﬁcant differences were found in
demographic/laboratory variables and diabetic peripheral polyneuro-
pathy between patients with and without liver ultrasound examina-
tion). In addition, another possible selection bias of this study is that
we included patients with type 1 diabetes, who attended a
foot-screening program (i.e., individuals at high risk for neuropathy;
indeed, a large part of our participants had a moderate-to-severe
symmetric polyneuropathy). Thus, our results cannot be necessarily
generalizable to other diabetic populations (e.g., individuals withmild
symmetric polyneuropathy). Thirdly, the diagnosis of distal symmet-
ric polyneuropathy was not conﬁrmed through measurement of
nerve-conduction velocities or skin biopsy, which represent the ‘gold
standard’ methods for diagnosing diabetic peripheral polyneuropa-
thy. Indeed, these invasive neurologic tests are restricted only to
selected patients and are not suitable for routinely use in clinical
practice, as they are time-consuming, patient-unfriendly, and costly,
and need to be performed by an expert operator. Conversely, we used
the MNSI clinical score. Although the MNSI clinical score dates back to
1994, it is still considered valid and it has been recently used to
measure peripheral neuropathy in high-risk non-diabetic,
pre-diabetic and newly diagnosed diabetic patients.26 Furthermore,
we used a biothesiometer instead of a 128-Hz tuning fork, as it is a
simple, reproducible and more accurate test than the 128-Hz tuning
fork.43 Importantly, in our patients, the assessment of diabetic
peripheral neuropathy by biothesiometer was based on VPT values
that have been previously validated in diabetic and non-diabetic
Italian individuals.44 Moreover, since our patients were participating
in a foot-screening program, we used a pathological cut-off of 25 Volt,
which is a VPT value associated with an increased risk of foot ulcers.45
Fourthly, although we adjusted our results for a number of potential
confounding factors, we cannot deﬁnitely exclude that residual and
unmeasured factors (e.g., cardiovascular autonomic neuropathy that
is also associated with NAFLD46) might partly explain the observed
association between NAFLD and distal symmetric polyneuropathy.
Finally, the diagnosis of NAFLD was based on ultrasonography, which
has a relatively low sensitivity in the presence of smaller amounts of
hepatic steatosis (i.e., b20%–30%), and was not conﬁrmed through
liver biopsy (the ‘gold standard’). However, we believe that it would
have been unethical to perform liver biopsies in our diabetic patients
with normal or only moderately elevated serum liver enzymes. In a
recent meta-analysis, Hernaez et al.30 showed that ultrasonography
enables a reliable and accurate detection of mild-to-moderate hepatic
steatosis compared to histology. In fact, these investigators reported
that the overall sensitivity, speciﬁcity, positive likelihood ratio, and
negative likelihood ratio of ultrasonography for detecting
moderate-to-severe fatty liver, compared to histology, were 84.8%,
93.6%, 13.3 and 0.16, respectively.30 Thus, although some
non-differential misclassiﬁcation of NAFLD based on ultrasonography
is likely, this limitation would attenuate the magnitude of our effect
measures toward null; therefore, our results are most likely a
conservative estimate of the association between NAFLD and distal
symmetric polyneuropathy.
Despite these limitations, our study has several important
strengths, such as the relatively large sample size, the performance
of neurologic examinations/tests by the same examiners (so reducing
the inter-observer variability), the ability to adjust for multiple
1026 A. Mantovani et al. / Journal of Diabetes and Its Complications 31 (2017) 1021–1026established risk factors, and the exclusion of patients with important
comorbidities, such as cirrhosis, end-stage renal disease or cancer.
Indeed, we believe that including patients with these complications
might have confounded our interpretation of data.
In conclusion, this retrospective, cross-sectional study is the ﬁrst to
show that NAFLD as diagnosed by ultrasonography was signiﬁcantly
associated with a ﬁvefold increased risk of prevalent distal symmetric
polyneuropathy in adult patients with type 1 diabetes. Notably, this
associationwas independent of multiple established cardio-metabolic
risk factors (including also glycemic control and metabolic syndrome
features). Further research is needed to determine whether NAFLD
increases the risk of developing distal symmetric polyneuropathy, and
to elucidate whether improvement in NAFLD (or future treatments
for NAFLD) will help to delay or prevent the development and
progression of distal symmetric polyneuropathy in type 1 diabetic
adults.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2017.01.024.
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